RATIONALE: Although convergent evidence exists for a role of glutamate in the regulation of anxiety, the involvement of specific glutamate receptor subtypes has yet to be defined. OBJECTIVE: To evaluate the potential for blockade of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate receptors to produce anxioltyic-like effects with the AMPA/GLU(K5) (kainate) antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5yl)ethyl]decahydroisoquinoline-3carboxylic acid (LY293558) MATERIALS AND METHODS: Punished responding of rats was used to determine the efficacy of LY293558. Other in vivo and in vitro studies further characterized the specificity of LY293558 for AMPA/kainate receptors. RESULTS: LY293558 had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro. In keeping with the low affinity of LY293558 for NMDA receptors, LY293558 was not effective in preventing NMDA-induced seizures in mice. LY293558 increased punished responding, a preclinical predictor of anxiolytic efficacy, at a dose that decreased unpunished responding (10 mg/kg, i.p.). Chlordiazepoxide produced comparable increases in both punished and unpunished responding. The NMDA antagonist dizocilpine [(+)-MK-801] also increased both punished and unpunished responding. CONCLUSIONS: These data along with those in the literature suggest that AMPA and/or kainate receptor blockade may be an important component to producing anxiolytic-like effects and may therefore be a target for compounds with efficacy in the therapeutic treatment of anxiety disorders.
RATIONALE: Although convergent evidence exists for a role of glutamate in the regulation of anxiety, the involvement of specific glutamate receptor subtypes has yet to be defined. OBJECTIVE: To evaluate the potential for blockade of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate receptors to produce anxioltyic-like effects with the AMPA/GLU(K5) (kainate) antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5yl)ethyl]decahydroisoquinoline-3carboxylic acid (LY293558) MATERIALS AND METHODS: Punished responding of rats was used to determine the efficacy of LY293558. Other in vivo and in vitro studies further characterized the specificity of LY293558 for AMPA/kainate receptors. RESULTS:LY293558 had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro. In keeping with the low affinity of LY293558 for NMDA receptors, LY293558 was not effective in preventing NMDA-induced seizures in mice. LY293558 increased punished responding, a preclinical predictor of anxiolytic efficacy, at a dose that decreased unpunished responding (10 mg/kg, i.p.). Chlordiazepoxide produced comparable increases in both punished and unpunished responding. The NMDA antagonist dizocilpine [(+)-MK-801] also increased both punished and unpunished responding. CONCLUSIONS: These data along with those in the literature suggest that AMPA and/or kainate receptor blockade may be an important component to producing anxiolytic-like effects and may therefore be a target for compounds with efficacy in the therapeutic treatment of anxiety disorders.
Authors: M J Procter; A K Houghton; E S Faber; B A Chizh; P L Ornstein; D Lodge; P M Headley Journal: Neuropharmacology Date: 1998 Oct-Nov Impact factor: 5.250
Authors: J H Krystal; D C D'Souza; I L Petrakis; A Belger; R M Berman; D S Charney; W Abi-Saab; S Madonick Journal: Harv Rev Psychiatry Date: 1999 Sep-Oct Impact factor: 3.732
Authors: D D Schoepp; D Lodge; D Bleakman; J D Leander; J P Tizzano; R A Wright; A J Palmer; C R Salhoff; P L Ornstein Journal: Neuropharmacology Date: 1995-09 Impact factor: 5.250
Authors: L Leanne Lash-Van Wyhe; Pekka A Postila; Koichi Tsubone; Makoto Sasaki; Olli T Pentikäinen; Ryuichi Sakai; Geoffrey T Swanson Journal: Neuropharmacology Date: 2009-12-04 Impact factor: 5.250
Authors: Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz Journal: J Neural Transm (Vienna) Date: 2016-09-14 Impact factor: 3.575
Authors: Paul J Fitzgerald; Chris Barkus; Michael Feyder; Lisa M Wiedholz; Yi-Chyan Chen; Rose-Marie Karlsson; Rodrigo Machado-Vieira; Carolyn Graybeal; Trevor Sharp; Carlos Zarate; Judith Harvey-White; Jing Du; Rolf Sprengel; Peter Gass; David Bannerman; Andrew Holmes Journal: Neurobiol Dis Date: 2010-08-08 Impact factor: 5.996
Authors: Gábor L Kapus; István Gacsályi; Miklos Vegh; Hajnalka Kompagne; Endre Hegedus; Csilla Leveleki; László G Hársing; József Barkóczy; András Bilkei-Gorzó; György Lévay Journal: Psychopharmacology (Berl) Date: 2008-03-25 Impact factor: 4.530
Authors: V Aroniadou-Anderjaska; V I Pidoplichko; T H Figueiredo; C P Almeida-Suhett; E M Prager; M F M Braga Journal: Neuroscience Date: 2012-07-13 Impact factor: 3.590
Authors: Edina K Cseh; Gábor Veres; Tamás Körtési; Helga Polyák; Nikolett Nánási; János Tajti; Árpád Párdutz; Péter Klivényi; László Vécsei; Dénes Zádori Journal: J Headache Pain Date: 2020-04-21 Impact factor: 7.277